TOP STORY Researchers Make Progress Toward Regenerating Tissue to Replace Joints Researchers have successfully regenerated rabbit joints using a cutting edge process to form the joint in vivo. In the study, bioscaffolds were infused with transforming growth factor beta 3 to promote growth of the rabbit joint. [Press release from the National Institutes of Health discussing online prepublication in The Lancet]
|
| SCIENCE NEWSGenetic Variations Responsible for High Triglyceride Levels Researchers have shown that a combination of both common and rare variants in several genes add up and put a patient at risk of developing hypertriglyceridemia. [Press release from the University of Western Ontario discussing online prepublication in Nature Genetics]Researchers Identify Key Enzyme in DNA Repair Pathway Researchers have discovered an enzyme crucial to a type of DNA repair that also causes resistance to a class of cancer drugs most commonly used against ovarian cancer. [Press release from the University of Texas MD Anderson Cancer Center discussing online prepublication in Science] Scientists Find Cell of Origin for Human Prostate Cancer Researchers proved that basal cells found in benign prostate tissue could become human prostate cancer in mice with suppressed immune systems, a finding that bucks conventional wisdom. [Press release from the University of California, Los Angeles discussing online prepublication in Science] Aging Cells Lose Protein Pumps A family of proteins that pump molecules across the cell membrane may help to explain why yeast cells, and perhaps the cells of other organisms, are not able to go on producing copies of themselves forever. The same proteins may also partly explain how stem and cancer cells keep dividing. [Press release from NatureNews discussing online prepublication in Nature Cell Biology] Obscure Immune Cells Thwart Ticks A study now shows that basophils help repel bloodthirsty ticks that can spread lethal diseases. The work also introduces a new method for teasing out further immune functions of the often-overlooked cells. [Press release from ScienceNow discussing online prepublication in The Journal of Clinical Investigation] Scientists Discover Cancer-Causing Gene — Helping to Distinguish Lung Cancer Subtypes Scientists have identified a cancer-causing gene, BRF2, specific to squamous lung cell carcinoma. [Press release from the British Columbia Cancer Agency discussing online prepublication in PLoS Medicine] Revolutionary Findings Prove Novel Mechanism of Stem Cells Researchers show that bone marrow cells not only turn into new heart muscle themselves but also stimulate the body’s own cardiac stem cells to go into overdrive to contribute to the repair process. [Press release from the University of Miami Miller School of Medicine discussing online prepublication in Circulation Research] Scientists 'Reprogram' Mouse Fat Cells into Clinically Useful Stem Cells Scientists from the Monash Institute of Medical Research have “reprogrammed” adult mouse fat cells and neural cells to become induced pluripotent stem cells. [Press release from EurekAlert! discussing online prepublication in Cell Transplantation] RNA Offers a Safer Way to Reprogram Cells Researchers have shown, for the first time, that they can deliver reprogramming genes using RNA. This method could prove much safer than DNA-based reprogramming. [Press release from Massachusetts Institute of Technology discussing online prepublication in PLoS One] Toxic Trio Identified as the Basis of Celiac Disease Scientists have identified the three protein fragments that make gluten toxic to people with celiac disease. [Press release from the Walter and Eliza Hall Institute of Medical Research discussing online prepublication in Science Translational Medicine] Therapeutic HIV Vaccines Show Promise Researchers presented the results of a handful of successful, but small, early-phase clinical trials for therapeutic vaccines — once thought to be a dead end for tackling HIV. [Press release from NatureNews discussing research presented at the XVIII International AIDS 2010 Conference] Geron to Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based Therapy Geron Corporation announced that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed. [Geron Corporation Press Release] Athersys Announces Positive Results from Phase I Study of Multistem® in Heart Attack Patients Athersys, Inc. announced positive results from its Phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction. [Athersys, Inc. Press Release] CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) Excess of Rare Variants in Genes Identified by Genome-Wide Association Study of Hypertriglyceridemia Through genome-wide association studies, researchers identified common variants in APOA5, GCKR, LPL and APOB associated with hypertriglyceridemia. [Nat Genet] Regeneration of the Articular Surface of the Rabbit Synovial Joint by Cell Homing: A Proof of Concept Study Researchers tested the hypothesis that the articular surface of the synovial joint can regenerate with a biological cue spatially embedded in an anatomically correct bioscaffold. [Lancet] FAN1 Acts with FANCI-FANCD2 to Promote DNA Interstrand Cross-Link Repair Researchers characterized a previously unrecognized nuclease, Fanconi anemia-associated nuclease 1 (FAN1), that promotes interstrand cross-linking repair in a manner strictly dependent on its ability to accumulate at or near sites of DNA damage and that relies on monoubiquitylation of the FANCI-FANCD2 complex. [Science] Identification of a Cell of Origin for Human Prostate Cancer Researchers show that basal cells from primary benign human prostate tissue can initiate prostate cancer in immunodeficient mice. [Science] Asymmetrically Inherited Multidrug Resistance Transporters Are Recessive Determinants in Cellular Replicative Aging Mutants lacking certain multidrug resistance (MDR) genes exhibited a reduced replicative lifespan (RLS), whereas introduction of only one extra copy of these MDR genes extended RLS. [Nat Cell Biol] Selective Ablation of Basophils in Mice Reveals Their Nonredundant Role in Acquired Immunity Against Ticks Data provide the first clear evidence that basophils play an essential and nonredundant role in antibody-mediated acquired immunity against ticks, which may suggest new strategies for controlling tick-borne diseases. [J Clin Invest] Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma Data suggest that genetic activation of BRF2 represents a unique mechanism of squamous cell carcinoma lung tumorigenesis through the increase of RNA polymerase III-mediated transcription. [PLoS Medicine] Bone Marrow Mesenchymal Stem Cells Stimulate Cardiac Stem Cell Proliferation and Differentiation Mesenchymal stem cells stimulate host cardiac stem cells, a new mechanism of action underlying successful cell-based therapeutics. [Circ Res] The Efficient Generation of Induced Pluripotent Stem (iPS) Cells from Adult Mouse Adipose Tissue-Derived and Neural Stem Cells Findings confirm that adipose tissue-derived cells are an ideal candidate as a readily accessible somatic cell type for high efficiency establishment of iPS cell lines. [Cell Transplant] Innate Immune Suppression Enables Frequent Transfection with RNA Encoding Reprogramming Proteins Researchers show that combined knockdown of interferon-beta (Ifnb1), Eif2ak2, and Stat2 rescues cells from the innate immune response triggered by frequent long-RNA transfection. Using this technique, they were able to transfect primary human fibroblasts every 24 hours with RNA encoding the reprogramming proteins Oct4, Sox2, Klf4, and Utf1. [PLoS One] Comprehensive, Quantitative Mapping of T Cell Epitopes in Gluten in Celiac Disease Findings show that pathogenic T cells in celiac disease show limited diversity, and therefore suggest that peptide-based therapeutics for this disease and potentially other strongly HLA-restricted immune diseases should be possible. [Sci Transl Med]
|
| | BUSINESSSTEMCELL Technologies Applauds Nature Protocol Article Published by Prominent HIV Lab at the Institut Pasteur Citing the Use of RoboSep® to Isolate CD4+ and CD8+ T Cells In a recent, high-impact Nature Protocol publication, Asier Sáez-Cirión and his group at the Institut Pasteur standardized the protocol for T cell-based HIV suppression. RoboSep®, the fully automated cell separator from STEMCELL Technologies, was the instrument of choice for cell isolation procedures. [STEMCELL Technologies Inc. Press Release] Sanofi-aventis Said to be Likely to Bid $18 Billion for Genzyme Sanofi-aventis is likely to make an unsolicited offer of up to $70 a share for Genzyme, raising the stakes for what could become one of the year’s biggest deals, people briefed on the matter said. [The New York Times] Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology Through 2023 Regeneron Pharmaceuticals, Inc. and Astellas Pharma Inc. announced that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune® technology in its internal research programs to discover fully human monoclonal antibody product candidates. [Regeneron Pharmaceuticals, Inc. Press Release] Charles River Announces Mutual Termination of Acquisition Agreement with WuXi PharmaTech Charles River Laboratories International, Inc. announced that it has mutually agreed with WuXi PharmaTech Inc. to terminate their previously announced acquisition agreement. [Charles River Laboratories International, Inc. Press Release] Canadian Researchers Testing Unique Vaccines for Prion Diseases and Common Cancers Several Canadian researchers have come together to help control the relentless spread chronic wasting disease in deer and elk through vaccines and to generate safe and effective therapies for common cancers. The multi-provincial research involves three scientists along with two industry partners, Amorfix Life Sciences Ltd. and PREVENT, the Pan Provincial Vaccine Initiative. [PrioNet Canada Press Release] British Companies to Receive Support to Develop New Regenerative Medicine Products and Technologies The government-backed Technology Strategy Board is to invest over £5 million to support the research and development in the UK of new regenerative medicine products, tools and technologies. 16 research and development projects in the field of regenerative medicine therapeutics are to receive a total of £3.6 million of investment, while a further £1.6 million is to be invested in 12 feasibility studies in the area of regenerative medicine tools and technologies. [Technology Strategy Board Press Release] Cerenis Therapeutics Raises EUR40 Million in Series C Financing Cerenis Therapeutics SA announced it has raised EUR40 million in the first close of its series C financing. [Cerenis Therapeutics SA Press Release] Immune Design Corporation Raises $32 Million in Series B Financing Immune Design Corporation announced that it has secured $32 million in Series B financing. [PR Newswire] Cytori Gains Stem Cell Device Approval in Europe for Breast Cancer Reconstruction and Soft Tissue Repair Cytori Therapeutics received expanded European approval for its Celution® System, a medical device that extracts and separates stem and regenerative cells from a patient's own fat tissue. [Cytori Therapeutics Press Release] FDA Grants Orphan Drug Status for Personalized Cancer Vaccine, BiovaxID®, Targeting Mantle Cell Lymphoma Biovest International, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. [Biovest International, Inc. Press Release] Oxford BioMedica Announces FDA Approval for TroVax® Phase II Study in Prostate Cancer Oxford BioMedica announced that it has received approval from the U.S. Food and Drug Administration (FDA) and Recombinant DNA Advisory Committee to initiate a clinical Phase II study in the United States to assess the activity of TroVax® (MVA-5T4) in patients with progressive hormone refractory prostate cancer. [Oxford BioMedica Press Release]
|
| | | |
| |
EVENTS (Listed by Date)
NEW XXIII International Congress of the Transplantation Society August 15-19, 2010 Vancouver, Canada CHI's 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS) August 17-19, 2010 Cambridge, United States Select Biosciences 3rd Annual Stem Cells Europe Conference August 24-25, 2010 Edinburgh, Scotland Select Biosciences 2nd Annual World Biobanking Summit August 24-25, 2010 Edinburgh, Scotland Select Biosciences Inaugural Cellular Therapy Summit August 24-25, 2010 Edinburgh, Scotland Viral Vectors in Gene Therapy: Applications and Novel Production Methods August 26-September 4, 2010 Kuopio, Finland NEW European Workshop on Skin Stem Cells August 31-September 2, 2010 Cambridge, United Kingdom Clinical Trials International Summit 2010 September 1-2, 2010 Shanghai, China NEW Third Annual Limbal Stem Cell Meeting September 10, 2010 Reading, United Kingdom International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting September 11-14, 2010 Belgirate, Italy Hydra VI: The European Summer School on Stem Cells & Regenerative Medicine September 11-17, 2010 Hydra, Greece Joint Metastasis Research Society – American Association of Cancer Research Conference on Metastasis and the Tumor Microenvironment September 12-15, 2010 Philadelphia, United States Stem Cells USA & Regenerative Medicine Congress 2010 September 13-15, 2010 Philadelphia, United States Select Biosciences 7th Annual RNAi & miRNA Europe September 14-15, 2010 Dublin, Ireland Select Biosciences Inaugural Epigenetics Europe Conference September 14-15, 2010 Dublin, Ireland Select Biosciences Inaugural Genomics Automation Europe Conference September 14-15, 2010 Dublin, Ireland Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010 September 15-17, 2010 Sydney, Australia NEW First Annual BIO India International Partnering Conference September 21-22, 2010 Hyderabad, India Cellular Therapy of Cancer Symposium – ATTACK Project Meeting September 24-27, 2010 Montpellier, France NEW International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations September 27-28, 2010 San Francisco, United States International Society for Cell and Gene Therapy of Cancer (ISCGT) Congress September 27-29, 2010 Doha, Qatar 4th American Association of Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development September 27-30, 2010 Denver, United States Select Biosciences 6th Annual Ion Channel Targets Conference September 28-29, 2010 Washington, DC, United States Cytokines 2010: Cytokines in Infectious Diseases, Autoimmune Disorders and Cancer October 3-7, 2010 Chicago, United States 2010 World Stem Cell Summit October 4-6, 2010 Detroit, United States 5th World Congress on Preventive & Regenerative Medicine (WCRM) October 5-7, 2010 Hannover, Germany 17th Annual Meeting German Society for Gene Therapy (DG-GT e.V.) October 6-9, 2010 Munich, Germany COGEM Symposium: GM Viruses as Medicine: Panacea or Pandora's Box? October 7, 2010 Amsterdam, The Netherlands American Association of Blood Banks (AABB) Annual Meeting & Cellular Therapy and Transfusion Medicine Expo (CTTXPO) 2010 October 9-12, 2010 Baltimore, United States NEW 18th Annual BioPartnering Europe October 10-12, 2010 London, United Kingdom NEW New York Stem Cell Foundation Fifth Annual Translational Stem Cell Research Meeting October 12-13, 2010 New York, United States Translational Cancer Research for Basic Scientists October 17-22, 2010 Boston, United States NEW 2010 NanoMedicine Summit October 18-19, 2010 Cleveland, United States European Society of Gene and Cell Therapy (ESGCT) 18th Annual Congress October 22-25, 2010 Milan, Italy 3rd Annual Dubai Congress on Anti-Aging and Aesthetic Medicine (DCAAAM) October 26-27, 2010 Dubai, United Arab Emirates World Stem Cells & Regenerative Medicine Congress Asia 2010 October 26-29, 2010 Singapore City, Singapore Select Biosciences 3rd Annual Molecular Diagnostics World Congress October 28-29, 2010 San Diego, United States Fraunhofer Life Science Symposium 2010 October 29-30, 2010 Leipzig, Germany Stem Cell Society Singapore Symposium 2010: Translating Science to Therapy November 2-3, 2010 Singapore City, Singapore World Cord Blood Congress November 4-7, 2010 Marseille, France Select Biosciences 5th Annual European Biomarkers Summit November 9-10, 2010 Florence, Italy Select Biosciences International Forum on Stem Cells November 12-13, 2010 Tianjin, China Select Biosciences 2nd Annual RNAi Asia Conference November 15-16, 2010 Singapore City, Singapore 9th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases November 17-19, 2010 Sonoma, United States NEW 8th Annual Commercial Translation of Regenerative Medicine Conference November 18-19, 2010 London, United Kingdom Stem Cell Network 10th Annual Scientific Meeting November 22-24, 2010 Calgary, Canada NEW HealthTech and Medicines Knowledge Transfer Network 7th Annual BioProcessUK Conference November 24-25, 2010 Manchester, United Kingdom Tissue Engineering & Regenerative Medicine International Society (TERMIS) – North America 2010 Annual Conference December 5-8, 2010 Orlando, United States Select Biosciences 5th Annual Stem Cells World Congress January 24-25, 2011 San Diego, United States Phacilitate 7th Annual Cell & Gene Therapy Forum 2011 January 24-26, 2011 Washington DC, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News. Visit here to post your career opportunities.
|
| |
|